809 related articles for article (PubMed ID: 18480609)
1. Levodopa-induced dyskinesias in Parkinson's disease: etiology, impact on quality of life, and treatments.
Encarnacion EV; Hauser RA
Eur Neurol; 2008; 60(2):57-66. PubMed ID: 18480609
[TBL] [Abstract][Full Text] [Related]
2. Drug insight: Continuous dopaminergic stimulation in the treatment of Parkinson's disease.
Olanow CW; Obeso JA; Stocchi F
Nat Clin Pract Neurol; 2006 Jul; 2(7):382-92. PubMed ID: 16932589
[TBL] [Abstract][Full Text] [Related]
3. Pathophysiology of motor fluctuations in Parkinson's disease.
Widnell K
Mov Disord; 2005; 20 Suppl 11():S17-22. PubMed ID: 15822108
[TBL] [Abstract][Full Text] [Related]
4. Preventing levodopa-induced dyskinesias.
Olanow CW; Obeso JA
Ann Neurol; 2000 Apr; 47(4 Suppl 1):S167-76; discussion S176-8. PubMed ID: 10762145
[TBL] [Abstract][Full Text] [Related]
5. Levodopa-induced dyskinesias in Parkinson's disease: is sensitization reversible?
Bejjani BP; Arnulf I; Demeret S; Damier P; Bonnet AM; Houeto JL; Agid Y
Ann Neurol; 2000 May; 47(5):655-8. PubMed ID: 10805339
[TBL] [Abstract][Full Text] [Related]
6. [Development of dyskinesias induced by treatment for Parkinson's disease: potential role of first exposure to L-DOPA (or phenomenon of priming)].
Damier P; Tremblay L; Féger J; Hirsch EC
Rev Neurol (Paris); 2000 Mar; 156(3):224-35. PubMed ID: 10740093
[TBL] [Abstract][Full Text] [Related]
7. [Management of levodopa-induced dyskinesia].
Rascol O; Ferreira JJ; Payoux P; Brefel-Courbon Ch; Montastruc JL
Rev Neurol (Paris); 2002 Dec; 158 Spec no 1():S117-24. PubMed ID: 12690671
[TBL] [Abstract][Full Text] [Related]
8. [Management of Parkinson's disease in 2009].
Maertens de Noordhout A
Rev Med Suisse; 2009 Aug; 5(214):1650-5. PubMed ID: 19772196
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic strategies to prevent and manage dyskinesias in Parkinson's disease.
Pilleri M; Antonini A
Expert Opin Drug Saf; 2015 Feb; 14(2):281-94. PubMed ID: 25483147
[TBL] [Abstract][Full Text] [Related]
10. Pathophysiology of levodopa-induced dyskinesia: potential for new therapies.
Bezard E; Brotchie JM; Gross CE
Nat Rev Neurosci; 2001 Aug; 2(8):577-88. PubMed ID: 11484001
[TBL] [Abstract][Full Text] [Related]
11. The therapeutic concept of continuous dopaminergic stimulation (CDS) in the treatment of Parkinson's disease.
Stocchi F
Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 3():S68-71. PubMed ID: 20083012
[TBL] [Abstract][Full Text] [Related]
12. [Pharmacological mechanisms of the treatment of dyskinesias in Parkinson disease].
Jiménez-Jiménez FJ; Molina JA; Ortí-Pareja M
Rev Neurol; 1999 May 1-15; 28(9):889-98. PubMed ID: 10390756
[TBL] [Abstract][Full Text] [Related]
13. [Social and economic cost of L-Dopa-induced dyskinesias in patients with Parkinson's disease].
Maurel F; Lilliu H; Le Pen C
Rev Neurol (Paris); 2001 May; 157(5):507-14. PubMed ID: 11438770
[TBL] [Abstract][Full Text] [Related]
14. Optimizing long-term therapy for Parkinson disease: levodopa, dopamine agonists, and treatment-associated dyskinesia.
Stacy M; Galbreath A
Clin Neuropharmacol; 2008; 31(1):51-6. PubMed ID: 18303491
[TBL] [Abstract][Full Text] [Related]
15. An approach to the continuous dopaminergic stimulation in Parkinson's disease.
Schwartz M; Sabetay S
Isr Med Assoc J; 2012 Mar; 14(3):175-9. PubMed ID: 22675859
[TBL] [Abstract][Full Text] [Related]
16. Levodopa in the treatment of Parkinson's disease: current controversies.
Olanow CW; Agid Y; Mizuno Y; Albanese A; Bonuccelli U; Damier P; De Yebenes J; Gershanik O; Guttman M; Grandas F; Hallett M; Hornykiewicz O; Jenner P; Katzenschlager R; Langston WJ; LeWitt P; Melamed E; Mena MA; Michel PP; Mytilineou C; Obeso JA; Poewe W; Quinn N; Raisman-Vozari R; Rajput AH; Rascol O; Sampaio C; Stocchi F
Mov Disord; 2004 Sep; 19(9):997-1005. PubMed ID: 15372588
[TBL] [Abstract][Full Text] [Related]
17. Levodopa-induced dyskinesia in Parkinson's disease: clinical features, pathogenesis, prevention and treatment.
Thanvi B; Lo N; Robinson T
Postgrad Med J; 2007 Jun; 83(980):384-8. PubMed ID: 17551069
[TBL] [Abstract][Full Text] [Related]
18. Abnormal bidirectional plasticity-like effects in Parkinson's disease.
Huang YZ; Rothwell JC; Lu CS; Chuang WL; Chen RS
Brain; 2011 Aug; 134(Pt 8):2312-20. PubMed ID: 21742734
[TBL] [Abstract][Full Text] [Related]
19. Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications.
Olanow CW; Obeso JA; Stocchi F
Lancet Neurol; 2006 Aug; 5(8):677-87. PubMed ID: 16857573
[TBL] [Abstract][Full Text] [Related]
20. Treatments for Parkinson disease--past achievements and current clinical needs.
Poewe W
Neurology; 2009 Feb; 72(7 Suppl):S65-73. PubMed ID: 19221317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
